In this Commentary article published in the Special Focus Issue in Future Virology on the COVID-19 pandemic, researchers study the safety of different populations in regard to the spread of disease.
Browsing: Disease Area > Viral
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
In this Special Report from the ‘COVID-19: studying the global pandemic’ Special Focus Issue authors theorize about the identification of asymptomatic patients and the impact this has on the spread of COVID-19.
An epidemiological study has revealed that COVID-19 outcomes are better in those countries that have undertaken a TB vaccination regime in the last 15 years.
In this interview with Alessandra Renieri we hear about the GEN-COVID network in Italy working to dsicover the genetic variability in COVID-19 patients who show phenotypic differences and what this means for treating the disease.
A study undertaken in South Korea has shown that the viral load in asymptomatic COVID-19 patients is the same as in those who show symptoms of the disease and this could be contributing to the spread of the infection in populations.
An update on the state of knowledge on the COVID-19 pandemic and how this pertains to health including the influence on antiviral strategies to stop the spread of the virus and potential treatments for the disease.
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
A research team from The Rosalind Franklin Institute, Diamond Light Source, The University of Oxford and Public Health England have engineered nanobodies from llama antibodies that show protective immune effects against SARS-CoV-2.